Addressing Regulatory Uncertainty and Restoring Transparency

The FDA has resumed its policy of publicly releasing Complete Response Letters (CRLs) for new drug applications, which was temporarily suspended in April following a citizen petition. This action makes available 14 CRLs, including those for HLB (028300.KQ), a company listed on the KOSDAQ, and Grace Therapeutics (GRCE), a company listed on the NASDAQ. This move demonstrates that the U.S. Department of Health and Human Services (HHS) and the FDA's commitment to "Radical Transparency" remains strong, despite market concerns. By transparently disclosing the detailed reasons for regulatory decisions, investors can better understand and manage risks.

HLB's Third CRL for Liver Cancer Drug and Manufacturing Challenges

Among the publicly released documents, the most notable is the third CRL for the liver cancer drug co-developed by HLB's U.S. subsidiary, Elevar Therapeutics, and Jiangsu Hengrui Pharmaceuticals (600276.SS). The combination therapy of camrelizumab (an anti-PD-1 antibody) and rivoceranib (a VEGFR-2 inhibitor) was expected to be a first-line treatment for hepatocellular carcinoma (HCC). However, the CRL cited issues related to Chemistry, Manufacturing, and Controls (CMC) and cGMP compliance during the Phase 3 CARES-310 trial. Importantly, the FDA did not raise any concerns about the clinical efficacy or safety of the two drugs. This suggests that while early commercialization is delayed, the drug can be resubmitted for approval after addressing the manufacturing deficiencies.

Grace Therapeutics' Technical Deficiencies

The CRL for GTx-104, Grace Therapeutics' treatment for aneurysmal subarachnoid hemorrhage (aSAH), was also made public. GTx-104 is a new drug candidate developed as an intravenous formulation to improve the bioavailability and convenience of the existing oral drug, nimodipine (an L-type calcium channel blocker), and has completed a Phase 3 trial (STRIVE-ON). The FDA acknowledged the efficacy demonstrated in the clinical trial but cited issues with leachables from the packaging container and deficiencies in the CMO's quality control. The FDA's rigorous CMC review is intended to protect patient safety, but it also presents a significant hurdle for small and medium-sized biotech companies.

Improving the Biopharma Ecosystem and Future Outlook

This resumption of large-scale CRL releases sends a clear warning message to the global pharmaceutical industry: strengthening CMC capabilities is crucial for new drug development. It is now clear that managing manufacturing hygiene and supply chain is as important as achieving statistically significant clinical data. In particular, the fact that most of the 14 CRLs cited manufacturing deficiencies rather than efficacy issues suggests that companies will pay more attention to selecting manufacturing partners. In the long term, transparent information disclosure is expected to eliminate market speculation and promote a healthier biopharma ecosystem by encouraging investment in proven platforms.